32 results about "Trigeminal nerve" patented technology

The invention discloses trigeminal nerve electrical stimulation equipment and a use method thereof, and relates to the technical field of nerve treatment.The trigeminal nerve electrical stimulation equipment comprises an electrical stimulator and a remote controller, the electrical stimulator is fixedly connected with a connector, a wire is inserted into the connecting end of the connector, the connector fixes the wire, and the connector is connected with the remote controller. The outer side of the tail end of the wire is fixedly connected with a plurality of electrode slices, the outer side of the wire is fixedly connected with a plurality of anchor points located at the front ends of the electrode slices, and the remote controller is in wireless communication connection with the electrical stimulator. The device can be buried in the body of a patient for a long time, so that the effect of inhibiting the pain of the patient can be guaranteed, multiple operations for inhibiting the pain of the patient are not needed after one operation when the pain fed back by the patient still exists, and the damage to the body of the patient is reduced.

The invention discloses a flavor modifier, atomized essence and an aerosol generating device, and relates to the technical field of essence. According to the technical scheme, the flavor modifier comprises an active agent, a compound containing a phenolic hydroxyl group and-O-beta-D-glucosidic bond or a compound containing an alcoholic hydroxyl group and-O-beta-D-glucosidic bond is selected as the active agent, and the flavor modifier can be weakly combined with a Piezo channel in a trigeminal nerve to directly modulate a trigeminal nerve mechanoreceptor, so that the flavor of the trigeminal nerve is improved. The activity of the Piezo channel is inhibited, so that the sensitivity of the Piezo channel to mechanical friction of aerosol particles is reduced, and the nasal cavity roughness is reduced. Meanwhile, the flavor modifier disclosed by the invention can also cooperate with olfactory signals transmitted by other components in the atomized essence to jointly improve the smoothness, the fineness and the overall moist feeling of the fragrance.

The application discloses a device for judging the decompression effect of intraoperative trigeminal neuralgia, and relates to the technical field of medical monitoring devices, comprising a forceps body, a collection probe is arranged at the tip of the forceps body, a wiring box is arranged on the side of the forceps body away from the collection probe, a distance adjusting mechanism and an auxiliary center positioning mechanism are arranged between the wiring box and the forceps body, the forceps body with adjustable spacing and the distance adjusting mechanism are arranged, the flexible adjustment of the spacing of the collection probe is achieved, the overall signal of the ganglion segment can be detected by increasing the spacing, the smaller nerve area can be focused by reducing the spacing, the signal difference under different spacings is compared, the compression point is accurately positioned, blind decompression is avoided, the auxiliary center positioning mechanism is arranged, the center point of the forceps body and the corresponding position of the collection probe are quickly positioned, the medical staff accurately aims at the trigeminal nerve to be detected, the positioning deviation is avoided, the collection signal is not inaccurate, the trigeminal neuralgia clustering neural network algorithm is combined, a visual distribution view is generated, and the accuracy of decompression effect judgment and the operation efficiency are improved.

Provided are methods for treating trigeminal nerve pain in a subject in need thereof. The method may include administering to the subject by perineural injection of the trigeminal nerve a therapeutically effective amount of a composition comprising an alpha-2 adrenergic agonist, such as guanfacine. The composition may further comprise lidocaine.

Botulinum toxin for use in treating asthma in a patient in need thereof is provided. The treatment comprises administering botulinum toxin to the patient. The botulinum toxin may be administered by subcutaneous or intradermal injection. The subcutaneous or intradermal injection may be administered to and / or around the vicinity of a trigeminal nerve, a cervical nerve, a thoracic nerve, a lumbar nerve, a sacral nerve, or a combination thereof of the patient.

In some embodiments, disclosed herein are systems and methods of treating a patient that can include the steps of accessing the sphenopalatine fossa, and cannulating the inferior orbital fissure from the sphenopalatine fossa to access the retro-orbital space. The sphenopalatine fossa can be accessed via various routes, including percutaneously. Accessing the sphenopalatine fossa can include the step of inserting a needle-catheter system into the sphenopalatine fossa. Integrated needle-catheter systems as described herein can also be configured to access the trigeminal ganglion, epidural space, intrathecal space, and other desired anatomical locations.

In an illustrative embodiment, methods and systems for treating uterine bleeding include applying, at least every other day in which a subject exhibits or is expected to exhibit menstrual bleeding, neurostimulation therapy in one or more sessions, each session having a duration of at least five minutes, the neurostimulation therapy including applying electrical neurostimulation or mechanical neurostimulation to directly and / or indirectly activate one or more neural targets, the one or more neural targets including a trigeminal cervical complex and / or vagal efferent fibers. The neurostimulation therapy may be configured to enhance platelet function of the subject, thereby reducing a total volume of blood loss over a course of the menstrual bleeding.

The invention discloses siRNA (small interfering Ribonucleic Acid) targeting BACH1 and application of the siRNA in preparation of chronic pain treatment medicines, belongs to the field of biological medicines, and discloses a compound, a composition and a method for regulating BACH1 gene expression, regulating response of activity and regulating characters, diseases or conditions of a BACH1 gene expression pathway. A behavioral result shows that the group of siRNAs can significantly inhibit mechanical hyperalgesia generated by peripheral nerve injury induction; the siRNA is injected into the trigeminal ganglion of a neuropathic pain model mouse, molecular biology experiments show that the siRNA can remarkably reduce expression of BACH1 in the trigeminal ganglion of the mouse in vivo, a new target and a new method are provided for research and development of chronic pain treatment drugs, non-chemical modification and chemical modification nucleic acid molecules of the targeted BACH1 gene are provided, and the application prospect is wide. The traditional Chinese medicine composition has a good medicine effect on chronic pain, lays a foundation for medicine preparation for treating chronic pain, and has great application and popularization value.

The invention belongs to the technical field of medicines, and particularly relates to a pharmaceutical composition for treating headache and a preparation method thereof. The pharmaceutical composition comprises the following raw materials in parts by weight: 30-40 parts of a pharmaceutical active component, 2-4 parts of a disintegrating agent, 6-11 parts of a filler and 0.2-0.5 part of a lubricant, the active pharmaceutical ingredient consists of porphyridium polysaccharide and manganese gluconate in a mass ratio of 1: (0.5-1). The action mechanisms of the two active components in the pharmaceutical composition are clear and complementary: porphyridium polysaccharide reduces the expression of a proinflammatory factor by inhibiting an NF-kappa B signal channel so as to relieve the stimulation to trigeminal nerve endings, and the porphyridium polysaccharide is mild in action and can avoid the potential influence of strong immunosuppression on the immune system of children; manganese gluconate blocks a CGRP receptor in a targeting manner, directly inhibits nerve ending sensitization and central pain signal transduction mediated by the pain-inducing peptide, and intervenes migraine attack from a key path.

The application discloses a pressure-measurable trigeminal nerve balloon device, and relates to the technical field of nerve treatment. The device comprises a connector and a syringe, one end of the connector is provided with a lead wire, one end of the lead wire penetrates through a catheter and extends to the outside of the catheter, the tail end of the lead wire is fixedly connected with a balloon body, and one end of the connector is fixedly connected with a connecting end. The device is provided with a three-way joint, a pressure gauge and a second threaded head, the outlet end of the syringe is inserted into the liquid end, then the piston column is pushed to move, the piston column divides the liquid in the syringe into two parts, and the two parts of the liquid are injected into the connector and the lead wire through the liquid end, the three-way joint, the second threaded head and the connecting end, then the liquid enters the balloon body through the lead wire, the balloon body is inflated to compress the trigeminal nerve, and the pressure in the balloon body can be detected through the pressure gauge, so that the dose of the injected developing liquid can be adjusted at any time.

A method of treating vertigo in a patient in need thereof comprises administering a botulinum toxin to the patient. The botulinum toxin may be administered by subcutaneous / intradermal injection. The subcutaneous / intradermal injection may be administered to and / or around the vicinity of a trigeminal nerve, a cervical nerve, a thoracic nerve, a lumbar nerve, and a sacral nerve of the patient.

The invention discloses a nasal delivery double-chain RNA / Mn < 2 + > nano-drug as well as a preparation method and application thereof in immunotherapy. And adding the polymer into a solution containing double-stranded RNA and manganese salt, and self-assembling to form the nasal delivery double-stranded RNA / Mn < 2 + > nano-drug. The invention provides a new technical scheme for the barrier of the BBB. The nano delivery system has the advantages in the aspects of overcoming the BBB and improving the in-vivo biological distribution of the drug, and the surface of the nano carrier is modified with a ligand targeted to an endothelial cell overexpression receptor, such as ApoE peptide and the like, so that the drug can be delivered to penetrate through the BBB; a non-invasive nasal-brain delivery strategy becomes a new scheme for improving drug availability and reducing toxic and side effects, the drug can bypass BBB and rapidly enter brain parenchyma through olfactory bulb and trigeminal nerve conduction pathways, and an immune drug delivered by the nasal cavity can rapidly enter nasopharynx-related lymphatic tissue (NALT) and is transferred to CLN through a lymphatic network around the nasal cavity, so that the immune drug can be rapidly delivered to the nasopharynx-related lymphatic tissue (NALT). Further, a potent local immune response aiming at the in-situ GBM is induced.

The present invention relates to reducing an activation of a trigeminal ganglion neuron or cell and related uses in treating or preventing migraine.

This disclosure relates to a method, device, and system used for identifying and treating responders to external nerve stimulation via a combination of a skin electrode assembly and a functional near-infrared spectroscopy (fNIRS) device. More specifically, this specification discloses a method for cutaneous stimulation of the trigeminal nerve, occipital nerve, vagus nerve, facial nerve and / or any of their branches, and a method for measuring cerebral blood flow in a target brain region.

The present disclosure relates a novel method of improving motor learning by stimulating the trigeminal nerves and / or the occipital nerves. In particular implementations, the method of improving motor learning in a subject comprising stimulating the trigeminal nerves and / or the occipital nerves of the subject with electrical stimulation of 50-150 Hz or 1-5 kHz. The electrical current is administered as a biphasic symmetric square waveform in 30 s intervals.

The invention relates to an edaravone oral instant film as well as a preparation method and application thereof, and belongs to the technical field of medicines. The invention relates to an edaravone oral instant film. The edaravone oral instant film is prepared from the following raw materials: edaravone, a film forming material and phospholipid, the phospholipid is one or more of soybean phospholipid, lecithin or hydrogenated soybean phospholipid, and the film-forming material is one or more of hydroxypropyl methyl cellulose, polyvinyl alcohol, polyethylene glycol or polyvinylpyrrolidone; the weight ratio of the edaravone to the film-forming material to the phospholipid is 1: (1-5): (1-5). The oral cavity instant film provided by the invention not only meets the requirement that the dissolution rate of the oral cavity instant film is greater than 30% under a non-leakage groove condition, but also can form nanoparticles which can remarkably penetrate through soft palate mucosa after meeting water, and is delivered into the brain through a trigeminal nerve path, so that the bioavailability and local drug concentration of edaravone are remarkably improved, and the oral cavity instant film is suitable for clinical application. Wide application prospects are realized in the application of treating nervous system diseases.

The invention discloses a space situation enhancement method and system based on a cortex fusion technology, and relates to the field of aerospace flight attitude perception. In order to solve the problems that an existing space situation perception intervention means cannot take effect in real time, a large number of cognitive resources are occupied and the like, a head tactile stimulation array is adopted in the scheme, flight attitude information is mapped into graded vibration feedback through a cortex tactile fusion technology, and low-delay transmission is achieved through a trigeminal neural pathway. The system comprises a vibration patch helmet, a closed-loop control module and a data transmission unit, stimulation points cover six areas such as the forehead and the top of the head, and single-point and combined vibration prompting is supported. According to the method, secondary cognitive processing of a pilot is not needed, airsickness and flight illusion risks are remarkably reduced, occupation of cognitive resources is minimized, real-time enhancement of space situation awareness in the flight process is achieved, and the method is suitable for flight auxiliary scenes of various aircrafts.

A wearable neural stimulation and sensing device includes a headband worn on a head. The surface of the headband has electrode mounting recesses that can flexibly mount a stimulation electrode and a sensing electrode. The stimulation electrode includes a shallow stimulation electrode and a deep stimulation electrode that can respectively perform trigeminal nerve stimulation (TNS) and temporal interference brain stimulation (TIBS) to implement non-invasive electrical stimulation for shallow and deep brain regions. The sensing electrode, used for electrical impedance tomography, monitors the physiological data of brain activity in real time. A control unit adjusts the electrical stimulation parameter of the stimulation electrode and the measurement parameter of the sensing electrode. A processing unit processes the obtained physiological data. The present invention features precise stimulation, compact size, and portability, making it suitable for the treatment and monitoring of neurodegenerative diseases, thereby improving the quality of life of patients.

The invention relates to the technical field of biological medicines, in particular to application of a CCR1 / 5 inhibitor Met-RANTES in inhibition of pathological pain of trigeminal nerves. According to the invention, CCR1 / 5 is taken as a therapeutic target of chronic pain, and a medicine which is remarkable in analgesic effect, small in side effect and capable of relieving chronic pain and improving pain mood is developed by combining the pharmacological function of an inhibitor Met-RANTES of CCR1 / 5. The Met-RANTES inhibits a central nervous system chemokine receptor CCRR1 / 5 in a targeted manner in a regular nasal administration manner, so that pathological mechanical pain-sensitive response and accompanying negative emotion caused by chronic compression of trigeminal nerves can be remarkably relieved, and pain feeling is relieved. In addition, the analgesic effect of the drug combination of the Met-RANTES and the carbamazepine is more obvious than that of the drug combination of the Met-RANTES and the carbamazepine which are independently used. The nasal delivery mode enables the medicine to directly reach the central nervous system, and reduces side effects of the whole body.

The invention discloses siRNA targeting UCN1 and application of siRNA in preparation of chronic pain treatment drugs, belongs to the technical field of biological medicines, and discloses a compound, a composition and a method for regulating UCN1 gene expression, regulating response of activity and regulating characters, diseases or conditions of a UCN1 gene expression pathway. A behavioral result shows that the group of siRNAs can significantly inhibit mechanical hyperalgesia generated by peripheral nerve injury induction; the siRNA is injected into the trigeminal ganglion of a neuropathic pain model mouse, molecular biology experiments show that the siRNA can significantly reduce the expression of UCN1 in the trigeminal ganglion of the mouse in vivo, a new target and a new method are provided for research and development of chronic pain treatment drugs, non-chemically modified and chemically modified nucleic acid molecules of the targeted UCN1 gene are provided, and the application of the siRNA in treatment of chronic pain is promoted. The traditional Chinese medicine composition has a good medication effect on chronic pain, lays a foundation for medicine preparation for treating chronic pain, and has great application and popularization values.

The invention discloses siRNA (small interfering Ribonucleic Acid) targeting HSPB1 (Hepatitis B Protein B1) and application thereof in preparation of chronic pain treatment medicines, belongs to the field of biological medicines, and discloses a compound, a composition and a method for regulating HSPB1 gene expression, regulating response of activity and regulating characters, diseases or conditions of an HSPB1 gene expression pathway. A behavioral result shows that the group of siRNAs can significantly inhibit mechanical hyperalgesia generated by peripheral nerve injury induction; the siRNA is injected into the trigeminal ganglion of a neuropathic pain model mouse, molecular biology experiments show that the siRNA can significantly reduce expression of Hspb1 in the trigeminal ganglion of the mouse in vivo, a new target and a new method are provided for research and development of chronic pain treatment drugs, non-chemically modified and chemically modified nucleic acid molecules of the targeted HSPB1 gene are provided, and the application of the siRNA in treatment of chronic pain is promoted. The traditional Chinese medicine composition has a good medicine effect on chronic pain, lays a foundation for treating chronic pain, and has great application and popularization values.

There is provided a system for migraine treatment by transcutaneous electrical stimulation of a trigeminal nerve of a user, the system comprising: a stimulation device for attachment to a forehead of a user, wherein the stimulation device comprises an electrical stimulation means for transcutaneous electrical stimulation of the trigeminal nerve; and a processor configured to: receive one or more input parameters specific to the user, determine one or more user-specific treatment parameters depending on the received one or more input parameters, and transmitting the user-specific treatment parameters to the device.

The utility model relates to the technical field of medical instruments, and discloses a multifunctional nano spraying device based on nasal-brain rapid administration, which comprises a nozzle and a spraying bottle, the nozzle is arranged at the upper end of the spraying bottle; the spray bottle comprises a bottle body with an opening in the upper end, a first sealing cover, a second connecting pipe, a third connecting pipe, a spring, a second sealing cover and a nano-micelle compression chamber; a through hole is formed in the middle of the first sealing cover, the third connecting pipe is arranged in the bottle body, the upper end of the third connecting pipe is connected with one end of the second connecting pipe, the other end of the second connecting pipe is connected with one end of the nano-micelle compression chamber, the nano-micelle compression chamber is arranged in the second sealing cover, and the other end of the nano-micelle compression chamber is communicated with the nozzle. The device can assist a patient to inhale the medicine skillfully and deliver the medicine into the brain in a targeted manner. The direct way is that the medicine is inhaled to the brain area through olfactory nerve and trigeminal nerve cells, so that medicine metabolism, medicine side effects and non-specific aggregation caused by peripheral circulation are avoided.

To provide a botulinum toxin for treating neuropsychiatric disorders and / or neurological disorders.SOLUTION: Provided is a botulinum toxin for use in the treatment of ASD (autism) in a patient in need thereof. Said treatment comprises administration of botulinum toxin to said patient by subcutaneous / intradermal injection. Administration to adults comprises injecting 2-4 units into and / or around the trigeminal nerve, 2-4 units into and / or around the cervical nerve outside the patient's spine, 2-4 units into and / or around the thoracic nerve outside the patient's spine, 2-4 units into and / or around the lumbar nerve outside the patient's spine, and / or 2-4 units into and / or around the sacral nerve outside the patient's spine. The total dosage of botulinum toxin for an adult human weighing about 150 pounds is no more than about 50 units, adjusted for age, weight, or a combination thereof.SELECTED DRAWING: None

We provide formulations of ion channel modulators. [Solution] The present invention partially relates to compositions or dosage forms comprising condensed heteroaryl compounds useful for preventing and / or treating diseases or conditions associated with abnormal function of voltage-gated sodium ion channels, such as abnormal delayed / persistent sodium currents. Methods for treating diseases or conditions associated with abnormal function of sodium ion channels, including neurological disorders (e.g., Dravet syndrome, epilepsy), pain, neuromuscular disorders, trigeminal-autonomic headache (TAC), migraines, cranial nerve disorders or polycranial nerve disorders, and cortical spreading depression (CSD), are also provided herein. In another aspect, the present invention provides methods for producing ion channel modulators.

This invention discloses the application of substances that regulate the pain microenvironment and reshape the balance of the ascending pain perception-descending inhibition pathway in the preparation of drugs for the prevention and treatment of trigeminal neuralgia. It also verifies that after trigeminal nerve injury, the levels of reactive oxygen species (ROS) and TRPA1 channel protein expression increase in trigeminal neuralgia (TG). Improving the oxidative stress environment and silencing the NRF2 gene to assist in the regulation of TRPA1 channel protein can effectively downregulate the expression of pro-analgesic and inflammatory factors, significantly reducing orofacial pain sensitivity. This invention uses the pain microenvironment and the ascending pain perception-descending inhibition pathway as novel targets, providing specific drugs and diagnostic tools for the treatment of trigeminal neuralgia, and has significant clinical value.

The present disclosure relates to methods, devices, and systems for identifying and treating responders to external nerve stimulation via a combination of a skin electrode assembly and a functional near infrared spectroscopy (fNIRS) device. More specifically, disclosed herein are dermatological methods of stimulating trigeminal, occipital, vagus, facial nerves, and / or any branch thereof and measuring cerebral blood flow at a targeted brain region.

To provide a system and method for acute non-invasive treatment of a migraine attack.SOLUTION: The system comprises at least one skin electrode for placement on the forehead of a patient. The system is configured for providing consecutive biphasic electrical pulses via the at least one skin electrode to the supratrochlear and supraorbital nerves of the ophthalmic nerve branch of the trigeminal nerve during a prolonged time span. Preferably, the time span is at least 10 minutes.SELECTED DRAWING: Figure 2B

The invention provides a lipidosome for treating neuroinflammation as well as a preparation method and application thereof. The lipidosome comprises a carrier formed by assembling phospholipid, cholesterol and an amphiphilic polymer coupled with R peptide, and a medicine loaded on a hydrophobic layer of the carrier, the amino acid sequence of the R peptide comprises ERRPRGRRRGRKC; the medicine comprises any one or a combination of at least two of quercetin, curcumin, rutin, tripterine and drunkenin A. The invention further discloses a preparation method of the medicine. The surface of the carrier is subjected to R peptide functional modification, so that the interaction with epithelial cells of a nasal cavity can be enhanced, and the delivery efficiency of intranasal administration is improved; the endocytosis pathway is regulated and controlled to realize efficient internalization of the medicine, and the medicine is directly delivered to the central nervous system by bypassing the blood brain barrier through olfaction and trigeminal nerve pathways, so that the treatment of neuroinflammation is realized.

The invention provides a craniofacial skeleton organoid controlled by sensory organs and sensory nerves and a preparation method thereof, and relates to the technical field of biologication.The preparation method comprises the steps that in a three-dimensional matrix, human pluripotent stem cells are induced through morphogenetic gradient driving to form nerve ectoderm with a nerve tube head-tail axis and a nerve tube back-abdominal axis; the neural ectoderm is respectively differentiated into a neural crest cell flow carrying head-tail axis position information, a visual cranium substrate-like structure carrying head-tail axis position information, an olfactory cranium substrate-like structure carrying head-tail axis position information and a trigeminal nerve cranium substrate-like structure carrying head-tail axis position information; and a craniofacial skeleton organ is formed under mediation of nerve cadherin. The technical problem that in the prior art, a method for forming a craniofacial skeleton organ through induction cannot form a sensory organ and a sensory nerve innervation function is solved.